EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study

Claire Miller, Roberto Sommavilla, Donal Murphy, Thomas Morris, Mahmuda Khatun, Marie Cullberg

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15831 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Claire Miller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Food-Drug Interactions, Reducing Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This two‐part, adaptive study assessed the effect of food and an acid‐reducing agent (rabeprazole) on the pharmacokinetics (PK) and safety of capivasertib, a potent AKT inhibitor, in clinical development for cancer treatment.

Methods

In Part 1, healthy participants (n = 24) were randomized to receive single‐dose capivasertib after overnight fasting, a high‐fat, high‐calorie meal and with rabeprazole postovernight fasting in one of six treatment sequences. Based on Part 1 results, a new group of participants (n = 24) were randomized (Part 2) to receive capivasertib after overnight fasting, a low‐fat, low‐calorie meal and modified fasting (food restricted from 2 h before dosing to 1 h postdose) in one of six treatment sequences. Blood samples were collected for PK analyses.

Results

Following a high‐fat, high‐calorie meal, capivasertib exposure increased versus overnight fasting (geometric mean ratio [GMR] [90% confidence interval (CI)]: area under the concentration‐time curve [AUC inf ] 1.32 [1.22, 1.43], maximum concentration [ C max ] 1.23 [1.08, 1.41]), but was comparable to that postmodified fasting (GMR: AUC inf 1.13 [0.99, 1.29], C max 0.85 [0.70, 1.04]). AUC inf was similar and C max was lower with/without rabeprazole (GMR: AUC inf 0.94 [0.87, 1.02]), C max 0.73 [0.64, 0.84]). Capivasertib exposure was similar after a low‐fat, low‐calorie meal versus overnight fasting (GMR: AUC inf 1.14 [1.05, 1.25], C max 1.21 [0.99, 1.48]) or modified fasting (GMR: AUC inf 0.96 [0.88, 1.05], C max 0.86 [0.70, 1.06]). Safety was consistent with that in larger trials.

Conclusions

This study demonstrates that administering capivasertib with food or acid‐reducing agents does not lead to clinically relevant PK or safety profile changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food-Drug InteractionsReducing AgentsHumansAdministration, OralArea Under CurveBiological AvailabilityCross-Over StudiesFastingHealthy VolunteersRabeprazolePyrimidinesPyrroles

Stichwörter der Autor:innen

AKT inhibitoracid-reducing agentcapivasertibfood effectfood interactionproton-pump inhibitorrabeprazole

Substanzen

RabeprazoleReducing AgentscapivasertibPyrimidinesPyrroles

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Late Developmental Oncology, AstraZeneca, Cambridge, UK.
  • Oral Product Development, AstraZeneca, Macclesfield, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Förderung

  • AstraZeneca

Zitieren

APA

Miller, C., Sommavilla, R., Murphy, D., Morris, T., Khatun, M., & Cullberg, M. (2023). The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15831

Vancouver

Miller C, Sommavilla R, Murphy D, Morris T, Khatun M, Cullberg M. The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15831

BibTeX
@article{Miller2023,
  author = {Miller, Claire and Sommavilla, Roberto and Murphy, Donal and Morris, Thomas and Khatun, Mahmuda and Cullberg, Marie},
  title = {The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15831}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche